contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nexstim-plc-conversion-of-stock-options-2023a-to-stock-options-2023b-and-2023c

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Nexstim är verksamt inom medicinteknik. Bolaget har utvecklat en icke-invasiv teknik för hjärnstimulering som kallas SmartFocus®. Det är en navigerad magnetisk stimuleringsteknik (nTMS) med 3D-navigering som ger inriktning av TMS till det specifika området av hjärnan. Tekniken är avsedd för behandling av svår depression och kronisk neuropatisk smärta. Bolaget grundades år 2000 och har sitt huvudkontor i Helsingfors.

Google Trendsin mukaan TMS:n ja Nexstimin kiinnostus on kaikkien aikojen huipussaan ja reilusti korkeamma kuin aiemmin!

https://www.nexstim.com/news-and-events/news/press-release/nexstim-plc-conversion-of-stock-options-2023a-to-stock-options-2023b-and-2023c Optio-oikeudet peliin. Mikä tulkinta arvon seuraajilla tästä?

Onhan siinä vedetty mutkia suoriksi.  Näin joulun alla sallittaneen ei varsinaisesti sijoitusaiheinen kuvanen, tekoälyn näkemys “Kirurgin työtä helpottavasta aivostimulaattorista.”  Tuopa on se simppelein tapa tulkita moinen härveli, real time augmented intelligence

Voisi olla järkevää kutsua taloustoimittajat tutustumaan Nexstimiin. Tuntuu että todella pimennossa on vielä kaikille toimittajille että mistä firmasta on kyse. Lisäksi esimerkiksi Tekniikan Maailmasta olisi mukava päästä lukemaan tästä suomalaisesta tulevasta menestystarinasta.

Joo tuo 9 millin kierroshan on puhtaasti siihen että kehittävät Nexstimin kanssa laitteen soveltuvuutta tuohon 3 faasiin ja ostavat 20 laitetta, jotta voivat hoitaa potilaita noissa 20 eri lokaatiossa.

Phase 3 ei kyllä tule 9M:llä pyöräytettyä millään, joten tämä lienee P3 starttipaketti, johan siitä suurin osa olisi jyvitetty teknologiakehitykseen Nexstimille.

Eikös tuo kierros ollut Phase 3 varten? Lukee molemmissa Phase 2

Nexstim

Company Announcement, Helsinki, 23 December 2024 at 3 PM (EET)Nexstim Plc: Conversion of stock options 2023A to stock options 2023B and 2023CNexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") ...

Company Announcement, Helsinki, 23 December 2024 at 3 PM (EET)Nexstim Plc: Conversion of stock options 2023A to stock options 2023B and 2023CNexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announced on 16 May 2023 the establishment of the 2023A-C stock option plan based on the authorization granted by the Annual General Meeting on 31 March 2023. The stock options of the stock option plan are marked with the symbols 2023A, 2023B, and 2023C.The Board decided to convert the stock options 2023A held by the company into stock options 2023B and 2023C, so that 8,763 stock options 2023A are converted to class 2023B, and 8,763 stock options 2023A are converted to class 2023C. After the conversion, 229,294 stock options are marked with the symbol 2023A, 255,583 are marked with the symbol 2023B, and 255,583 are marked with the symbol 2023C.Further information is available on the website <a>www.nexstim.com</a>, or by contacting:Leena Niemistö, Chair of Board of Directors +358 9 2727 170 <a href="mailto:leena.niemisto@nexstim.com">leena.niemisto@nexstim.com</a>The Company’s Certified Advisor is Carnegie Investment Bank AB (publ).About Nexstim PlcNexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.Nexstim shares are listed on Nasdaq First North Growth Market Finland.For more information, please visit <a href="http://www.nexstim.com">www.nexstim.com</a> <div> <hr> <div>Attachments</div> <div><a href="https://storage.googleapis.com/inderes-widgets-prod-assets/nexstim/attachments/83dba2c4-d4bc-4e7d-872f-4f9fefb3ff61/nexstim-plc-company-announcement-options-2023abc-23122024-final-en.pdf">Nexstim Plc_Company announcement_Options 2023ABC_23122024_FINAL_EN.pdf</a></div> </div>

Beställ vårt nyhetsbrev — inget användarkonto krävs!